ChroMedX Collaborates with Microfluidic and Microfabrication Experts for HemoPalm Cartridge Development
Toronto, Ontario--(Newsfile Corp. - March 23, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (FSE: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce it has entered into a collaboration with Dr. Ravi Selvaganapathy of McMaster University to assist in the design and development of prototype cartridges for the Company's patented HemoPalm blood analyzer system. The McMaster and ChroMedX partnership has been awarded an NSERC Engage...
2015-03-23 4:30 PM EDT
ChroMedX Submits US Provisional Patent Application for Recently Developed Aspects of HemoPalm Blood Analysis System
Toronto, Ontario--(Newsfile Corp. - March 10, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a second US Provisional Patent Application pertaining to the HemoPalm Cartridge and Analyzer system. The second US Provisional Patent Application No. 62/114,700 entitled "Joint Spectroscopic and Biosensor System for Point-of-Care Testing" was filed...
2015-03-10 3:30 PM EDT
ChroMedX Engages Biosensor Development Expert Stephen Cozzette
Toronto, Ontario--(Newsfile Corp. - January 26, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of Mr. Stephen Cozzette as a consultant on the HemoPalm project focussing on the electrochemical sensor and cartridge development aspects of the project. "We are very excited to add Stephens's expertise to the team. Mr. Cozzette is particularly skilful at...
2015-01-26 5:00 PM EST
ChroMedX Exhibits and Presents at Cantech ’15 in Toronto, Canada
Toronto, Ontario--(Newsfile Corp. - January 13, 2015) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the Company will be presenting and exhibiting at the Cantech '15 Technology Conference on Thursday, January 15, 2015 in Toronto, Ontario Canada. ChroMedX President and CEO, Dr. Wayne Maddever, will be conducting a feature presentation covering the Company's technologies...
2015-01-13 3:24 PM EST
ChroMedX 2014 Progress Update
Toronto, Ontario--(Newsfile Corp. - December 19, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is proud to report on the Company's corporate and developmental progress in 2014. ChroMedX listed in mid-July 2014 and has made significant progress in the development of its patented technologies as well as advancement of the Corporation as a public entity. "We are very pleased with the progress...
2014-12-19 4:15 PM EST
Chromedx Completes Acquisition of Automated Ultrafiltration Immunoassay Technology
Toronto, Ontario--(Newsfile Corp. - December 15, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the it has closed its previously announced acquisition of patent application PCT/CA2013/050935 related to Automated Ultrafiltration Technology and associated intellectual property ("AUF") from InvidX Corp., pursuant to an option agreement dated June 16, 2014 (the "Option...
2014-12-15 6:30 AM EST
ChroMedX Commences AUF Development with Aline Inc. and Spectrum Labs
Toronto, Ontario--(Newsfile Corp. - December 9, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the engagement of ALine Inc. as primary contractor for the development of its recently acquired Automated Ultrafiltration (AUF) Cartridge. The AUF cartridge will be used as part of an automated system in the preparation of plasma/serum samples for immunoassay or mass...
2014-12-09 4:30 PM EST
ChroMedX Acquires Automated Ultrafiltration Immunoassay Technology
Toronto, Ontario--(Newsfile Corp. - November 28, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce the acquisition of the Automated Ultrafiltration Technology "AUF" and associated intellectual property. "After thorough investigation of the technology, potential market, and development requirements we are very enthused to add the AUF technology to our portfolio. We found...
2014-11-28 3:53 PM EST
ChroMedX Announces Biosensor Development and HemoPalm Update
Toronto, Ontario--(Newsfile Corp. - November 24, 2014) - ChroMedX Corp. (the “Company”) (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide an update on the Company’s HemoPalm handheld analyser/Cartridge technology and the commencement of biosensor development. Lead contractor, Aline Inc. has taken delivery of the first batch of biosensors in Rancho Dominguez, CA. and the initial test programme has commenced. The...
2014-11-24 3:30 AM EST
Chromedx Announces Collaborative Project with McMaster University
Toronto, Ontario--(Newsfile Corp. - November 17, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that it has reached an agreement with McMaster University on a collaborative project. The collaborative Project led by ChroMedX Technical Advisory Board member Dr. Cynthia Balion will provide the necessary laboratory space for ChroMedX to handle and treat blood samples in the...
2014-11-17 3:30 AM EST
ChroMedX Engages Dr. Hai Shiene Chen as Asia Business Development Advisor
Toronto, Ontario--(Newsfile Corp. - November 11, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the “Company”), is pleased to announce the engagement of Dr. Hai Shiene Chen of ACGT Corporation of Toronto, Ontario to assist the Company in the international commercialization of its innovative point of care and in-vitro diagnostics technologies in the Asian market. Dr. Chen will assist the Company by pursuing development/commercialization opportunities for the Company’s blood...
2014-11-11 3:30 AM EST
ChroMedX Announces Operations Update and Advisory Board Appointment
Toronto, Ontario--(Newsfile Corp. - October 28, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to provide a HemoPalm development update and announce Dr. Cynthia Balion as the first appointment to the Company's Technical Advisory Board. Dr. Wayne Maddever, P.Eng., Chief Executive Officer of ChroMedX Corp. is pleased to provide the following update on the Company's HemoPalm...
2014-10-28 1:30 AM EDT
ChroMedX Announces HemoPalm Trademark and Intellectual Property Update
Toronto, Ontario--(Newsfile Corp. - October 23, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (Frankfurt: EIY2) (the "Company"), a developer of in vitro diagnostics and point-of-care technologies is pleased to announce that the trademark for the Company's patented HemoPalm technology has been allowed by the United States Patent and Trademark Office and will be officially registered when the HemoPalm is released commercially. The HemoPalm technology is currently covered by two issued and one...
2014-10-23 3:30 AM EDT
ChroMedX Corp Announces Grant of Options
Toronto, Ontario--(Newsfile Corp. - October 6, 2014) - ChroMedX Corp. (CSE: CHX) (OTC: MNLIF) (the "Company") announces that it has granted an aggregate of 600,000 options to purchase common shares of the Company exercisable at a price of $0.18 per share and expiring on October 6, 2017, to certain consultants of the Company. The consultants concerned bring expertise to the Company in several key areas. These include the electrochemical and spectroscopic technologies incorporated in the...
2014-10-06 3:26 PM EDT
ChroMedX Corp. Information to be Available through S&P Capital IQ Corporation Records Program
Toronto, Ontario--(Newsfile Corp. - September 26, 2014) - ChroMedX Corp. (OTC: MNLIF) (CSE: CHX) announced today that its company information would be made available via S&P Capital IQ Corporation Records Listing Program. As part of the program, a full description of ChroMedX Corp. will be published in the Daily News Section of Standard & Poors's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation...
2014-09-26 10:55 AM EDT
ChroMedX Corp Closes Oversubscribed Private Placement
Toronto, Ontario--(Newsfile Corp. - September 22, 2014) - ChroMedX Corp. (CSE: CHX) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Offering") for gross proceeds of CDN$614,500 through the issuance of 6,145,000 units (each a "Unit") at a price of CDN$0.10 per Unit. As a result of the Offering being oversubscribed, the board of directors increased the private placement offering from CDN$500,000 to CDN$650,000. Each Unit...
2014-09-22 4:23 PM EDT
Monarch Energy Changes Its Name to ChroMedX Corp.
Toronto, Ontario--(Newsfile Corp. - September 17, 2014) - Monarch Energy Limited (CSE: CHX) (the "Company") is pleased to announce that pursuant to articles of continuance dated September 8, 2014, Monarch Energy Limited has continued from the province of British Columbia to the Province of Ontario and has changed its name to "ChroMedX Corp." The common shares of the Company will begin trading under its new name on September 18, 2014 under the current trading symbol "CHX". About ChroMedX...
2014-09-17 3:19 PM EDT
Monarch Energy Announces Results of Annual and Special Meeting
Toronto, Ontario--(Newsfile Corp. - August 29, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") announces that the shareholders of the Company have approved, at the Annual General and Special Meeting held on August 29, 2014, all of the items set forth in the Company's management information circular dated July 30, 2014 and mailed to the shareholders, including: (i) change of the Company's name to ChroMedX Corp.; (ii) continuance of the Company from British...
2014-08-29 1:28 PM EDT
Monarch Energy as ChroMedX Ltd. Engages ALine Inc. for Development of HemoPalm Cartridges and Handheld Analyzer
Toronto, Ontario--(Newsfile Corp. - July 29, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") is pleased to announce that its wholly-owned subsidiary ChroMedX Ltd. has engaged ALine Inc. of Rancho Dominguez, CA as its primary contractor for the development of the Company's HemoPalm cartridge and analyzer technology. The goal is to complete construction of the prototype cartridge and analyzer to demonstrate functionality of the system by the first quarter of...
2014-07-29 11:10 AM EDT
Monarch Energy Commences Business in the Medical Diagnostics and Research Field
Toronto, Ontario--(Newsfile Corp. - July 11, 2014) - Monarch Energy Limited (CSE: CHX) (OTC: MNLIF) ("Monarch" or the "Company") is pleased to announce that the Company has commenced business in the in vitro medical diagnostics and point-of-care testing field under its wholly owned subsidiary ChroMedX Ltd. Technologies The Company will now focus its efforts on commercializing technologies, protected by issued and pending patents developed by Dr. James Samsoondar, the Company's Chief Science...
2014-07-11 2:49 PM EDT